Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PILOT: Liso-cel in 2L Transplant-Ineligible LBCL
NCT03483103Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2018
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of lisocabtagene maraleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Started Jul 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03483103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483103.